
Keywords: prostatic neoplasms; neoplasm metastasis; castration; drug therapy; androgen antagonistsADT, androgen deprivation therapy; AE, adverse event; AR, androgen receptor; AR-V, AR splice variant; COU-AA-302, Abiraterone Acetate in Asymptomatic or Mildly Symptom